Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AXDX 
Accelerate Diagnostics Inc (AXDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AXDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 46.3% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.53M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 41709 | Beta 0.55 | 52 Weeks Range 0.69 - 2.09 | Updated Date 04/2/2025 |
52 Weeks Range 0.69 - 2.09 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.5 | Actual -0.37 |
Profitability
Profit Margin - | Operating Margin (TTM) -281.68% |
Management Effectiveness
Return on Assets (TTM) -73.66% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 67962442 | Price to Sales(TTM) 1.5 |
Enterprise Value 67962442 | Price to Sales(TTM) 1.5 | ||
Enterprise Value to Revenue 5.81 | Enterprise Value to EBITDA -1.1 | Shares Outstanding 25043800 | Shares Floating 13303804 |
Shares Outstanding 25043800 | Shares Floating 13303804 | ||
Percent Insiders 37.29 | Percent Institutions 18.78 |
Analyst Ratings
Rating 5 | Target Price 1.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Accelerate Diagnostics Inc
Company Overview
History and Background
Accelerate Diagnostics, Inc. was founded in 2012 and went public in 2015. It focuses on developing and commercializing innovative solutions for rapid pathogen identification and antibiotic susceptibility testing in the field of infectious diseases.
Core Business Areas
- Rapid Diagnostics: Develops and markets in vitro diagnostics for rapid identification and antibiotic susceptibility testing of pathogens causing serious infections. The main product is the Accelerate Pheno system, which helps determine appropriate antibiotic therapies faster than traditional methods.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, CTO, and other key executives overseeing various departments such as R&D, sales, marketing, and operations. Organizational structure is likely functional with specialized teams reporting to department heads.
Top Products and Market Share
Key Offerings
- Accelerate Pheno System: A rapid in vitro diagnostic platform that identifies pathogens and determines antibiotic susceptibility. It reduces the time to results compared to traditional methods, aiding in faster and more targeted antibiotic therapy. Due to limited sales data, Accelerate's specific market share is hard to determine. Competitors include bioMu00e9rieux's Vitek 2, Cepheid's GeneXpert, and Bruker's MALDI Biotyper.
Market Dynamics
Industry Overview
The infectious disease diagnostics market is driven by increasing antibiotic resistance, rising healthcare costs, and the need for faster and more accurate diagnostic tests. The market is competitive and regulated.
Positioning
Accelerate Diagnostics aims to position itself as a leader in rapid diagnostics for infectious diseases, focusing on improving patient outcomes and reducing healthcare costs. Their competitive advantage lies in the speed and comprehensiveness of their Pheno system.
Total Addressable Market (TAM)
The global infectious disease diagnostics market is estimated at approximately $20 billion. Accelerate Diagnostics aims to capture a significant portion of this market by providing faster and more accurate diagnostic solutions.
Upturn SWOT Analysis
Strengths
- Rapid results compared to traditional methods
- Comprehensive antibiotic susceptibility testing
- Improved patient outcomes
- Potential to reduce healthcare costs
- CE-IVD marked and FDA Cleared
Weaknesses
- Limited market penetration
- High cost of the system
- Requires specialized training to use the system
- Sales growth challenges
Opportunities
- Expanding into new geographic markets
- Developing new diagnostic tests
- Collaborating with pharmaceutical companies
- Increasing awareness of antibiotic resistance
Threats
- Competition from established players
- Regulatory hurdles
- Price pressure
- Reimbursement challenges
- Slow adoption rates by hospitals and labs
Competitors and Market Share
Key Competitors
- BMY
- TMO
- BIIB
Competitive Landscape
Accelerate Diagnostics competes with larger, more established players in the infectious disease diagnostics market. While their technology offers advantages in speed and accuracy, their smaller size and limited resources pose challenges in competing effectively.
Major Acquisitions
bioMu00e9rieux
- Year: 2021
- Acquisition Price (USD millions): 420
- Strategic Rationale: bioMu00e9rieux acquired Accelerate Diagnostics to strengthen its position in the infectious disease diagnostics market and expand its portfolio of rapid diagnostic solutions.
Growth Trajectory and Initiatives
Historical Growth: Analyze pre-acquisition data for historical data only.
Future Projections: Company was acquired, so projections are no longer independent.
Recent Initiatives: Focus on increasing sales and marketing efforts, expanding product offerings, and forming strategic partnerships before acquisition.
Summary
Accelerate Diagnostics demonstrated innovative technology for rapid diagnostics in infectious diseases, and their acquisition by bioMu00e9rieux shows that the technology was very promising. Before the acquisition, the company faced challenges in achieving broad market adoption and sustained profitability due to the highly competitive landscape. Success will depend on integrating this technology into the parent company and executing effective sales and marketing strategies. Before the acquisition, it needed to focus on increasing market penetration and streamlining operations.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
DGX
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Press Releases
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Accelerate Diagnostics Inc
Exchange NASDAQ | Headquaters Tucson, AZ, United States | ||
IPO Launch date 1996-11-18 | CEO, President & Director Mr. Jack Phillips | ||
Sector Healthcare | Industry Medical Devices | Full time employees 107 | |
Full time employees 107 | |||
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.